Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Journal article
Moore SC. et al, (2023), Med (N Y)
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Journal article
Vatzia E. et al, (2023), NPJ Vaccines, 8
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster
Journal article
Ulaszewska M. et al, (2023), Human Vaccines & Immunotherapeutics
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Journal article
Tomic A. et al, (2022), Nature Communications, 13
Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro.
Journal article
Nyagwange J. et al, (2022), International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6.
Journal article
Dijokaite-Guraliuc A. et al, (2022), Cell discovery, 8
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
Journal article
Shaw RH. et al, (2022), The Lancet Respiratory Medicine, 10, 1049 - 1060
Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Journal article
Foster WS. et al, (2022), Cell reports. Medicine
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Journal article
Mentzer AJ. et al, (2022), Nature Medicine
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV.
Journal article
Fidler S. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Journal article
Madhi SA. et al, (2022), The Lancet. Infectious diseases
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 104298 - 104298
Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda.
Journal article
Atim SA. et al, (2022), The Journal of infection
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Journal article
van Doremalen N. et al, (2022), Nature Communications, 13
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
Journal article
McNaughton AL. et al, (2022), JCI Insight, 7
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Journal article
Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Journal article
Tuekprakhon A. et al, (2022), Cell, 185, 2422 - 2433.e13
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2022), The Journal of infection, 84, 795 - 813
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Journal article
Nutalai R. et al, (2022), Cell, 185, 2116 - 2131.e18
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet (London, England), 399, 2212 - 2225
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal article
Munro APS. et al, (2022), The Lancet. Infectious diseases
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Journal article
Ratcliff J. et al, (2022), Journal of clinical microbiology
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Journal article
Sharpe HR. et al, (2022), JCI Insight, 7
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
Journal article
van Doremalen N. et al, (2022), Res Sq
Response to Letter to the Editor by Ish et al. entitled ‘COVID-19 vaccine equity—the need of the hour’
Journal article
Maclean P. et al, (2022), QJM: An International Journal of Medicine
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Journal article
Waerlop G. et al, (2022), Frontiers in immunology, 13
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Journal article
Ogbe A. et al, (2021), Nature Communications, 12
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Journal article
Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2021), The Lancet, 397, 99 - 111